The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.

David J Kuter Alexandra Schifferli Tomás José González-López

Published in: British journal of haematology (2024)

Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients. Commentary on: Moulis et al. Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France Registry. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19288.

Keyphrases

end stage renal disease
ejection fraction
risk factors
peritoneal dialysis
social media
prognostic factors
health information
patient reported outcomes
patient reported